Evidence map›Paper›PMID 40791772›Full record

ArticleInternational journal of nanomedicine2025

Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice.

Chuncong Mo, Zhongfang Wang, Donglan Liu, Xiaoyun Yang, Qiong Zhang, Lihua Ye, Shuai Yuan, ShiDong Deng, Zhulan Lai, Deyi Huang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Chuncong Mo *State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Zhongfang Wang *State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Donglan Liu *Guangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.
Xiaoyun Yang *Guangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.
Qiong ZhangGuangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.
Lihua YeState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Shuai YuanHealth and Quarantine Laboratory, Guangzhou Customs District Technology Center, Guangzhou, Guangdong Province, 510700, People's Republic of China.
ShiDong DengState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Zhulan LaiGuangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.ORCID 0009-0009-1808-3485
Deyi HuangState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Yujie YangState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Duo XuGuangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.
Jinwei YuanGuangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.
Yuhui ZhuState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Haoyi LiuState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Chengxing ZhouGuangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.
Xiaohong LiaoGuangzhou National Laboratory, Guangzhou, Guangdong Province, 510005, People's Republic of China.
Xiao LiState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Wenkuan LiuState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Rong ZhouState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.
Xingui TianState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, 510182, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Adenovirus (Ad) vectors demonstrated significant efficacy as vaccine vectors during the COVID-19 pandemic. Hexon is the major capsid protein, and multiple hypervariable regions (HVRs) have been used for displaying exogenous antigens and inducing a strong antibody responses. Methods: We utilized SpyCatcher/SpyTag technology to incorporate SpyTag into HVR2, 4, and 7 of the hexon of the bivalent vaccine strain rAd3/7, respectively, to construct recombinant Ad, rAd3/7-SpyTag. The receptor-binding domain (RBD) of the SARS-CoV-2 BA5.2 strain fused with SpyCatcher was expressed as SpyCatcher-RBD, Spycatcher-RBD and rAd3/7-SpyTag were incubated in vitro to prepare a novel nanoparticle vaccine candidate, rAd3/7-SpyRBD, against SARS-CoV-2. Characterize rAd3/7-SpyRBD using Western blot, ELISA, transmission electron microscopy (TEM), and particle size measurement, and verify its immunogenicity through mouse immunization. Results: We have successfully established a universal nanoparticle vaccine platform, rAd3/7-SpyTag, and the RBD protein was successfully displayed on the surface of rAd3/7-SpyTag. Compared with SpyCatcher-RBD, rAd3/7-SpyRBD can rapidly induce the production of antibodies and stronger immune responses. Both Spycatcher-RBD and rAd3/7-SpyRBD provide a protective immune response against BA.5 in mouse model mice and can be used as candidates for SARS-CoV-2 vaccine. We also found that rAd3/7-SpyRBD induced the production of neutralizing antibodies against Ad3 and Ad7, suggested that it could serve as an Ads vaccine candidate. Conclusion: We developed a universal nanoparticle vaccine platform and obtained a trivalent vaccine candidate rAd3/7-SpyRBD, against SARS-CoV-2, Ad3, and Ad7, and this is the first time to use SpyCatcher/SpyTag technology in a bivalent rAd3/7 vector for trivalent immunity.

Indexed as

AdenoviridaeCapsid ProteinsCOVID-19COVID-19 VaccinesNanoparticlesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsCOVID-19 Vaccineshexon capsid protein, AdenovirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2adenovirusnanoparticlesSARS-CoV-2SpyTagvaccine

Identifiers

PMID40791772
PMCPMC12336385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.